TimothyLarsonMD

Oncology • Saint Paul, MN

Gastrointestinal Cancer, Thoracic Cancer

Medical Director Early Phase Therapeutics Program

Join to view full profile

Dr. Larson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Larson's full profile

Already have an account?

Office
640 Jackson St
200
Saint Paul, MN 55101
Phone+1 651-254-3321
Is this information wrong?

Education & Training

University of California Davis HealthFellowship, Hematology and Medical Oncology, 1992 - 1995
University of California Davis HealthResidency, Internal Medicine, 1989 - 1992
University of California San Francisco School of MedicineClass of 1989

Certifications & Licensure

CA State Medical License 1990 - Present
MN State Medical License 1995 - 2024
AZ State Medical License 1992 - 2018
FL State Medical License 1991 - 2018
OH State Medical License 2011 - 2018
TX State Medical License 2013 - 2018
WA State Medical License 2008 - 2017
NC State Medical License 2007 - 2012
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma Start of enrollment: 2021 May 12
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

3 citations
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomize...
Heinz-Josef Lenz, Aparna Parikh, David R Spigel, Allen L Cohn, Takayuki Yoshino
Journal for Immunotherapy of Cancer. 2024-03-13

Abstracts/Posters

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged _60 YearsClinically Relevant Abstract
Timothy Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above
Timothy Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019